Preclinical evaluation of a novel ATM inhibitor, KU59403, In Vitro and In Vivo in p53 functional and dysfunctional models of human cancer

Molecular Cancer Therapeutics

Volumn 12, Issue 6, 2013, Pages 959-967

  Batey, Michael A ^a   Zhao, Yan ^a   Kyle, Suzanne ^a   Richardson, Caroline ^b   Slade, Andrew ^b   Martin, Niall M B ^b   Lau, Alan ^b   Newell, David R ^b   Curtin, Nicola J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b KuDOS Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOFOS; ETOPOSIDE; IRINOTECAN; KU 59403; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHEMOSENSITIVITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CLEARANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; TISSUE DISTRIBUTION;

ANIMALS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MICE; NEOPLASMS; PYRONES; RADIATION-SENSITIZING AGENTS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879294844     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0707     Document Type: Article

References (22)

1. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23.
2. Chun HH, Gatti RA. Ataxia Telangiectasia, an evolving phenotype. DNA Repair (Amst) 2004;3:1187-96.
3. Shiloh Y. The ATM-mediated DNA damage response: taking shape. TIBS 2006;21:402-10.
4. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to doublestrand breaks. Science 1999;286:1162-6.
5. Riballo E, Kuhne M, Rief N, Doherty A, Smith GC, Recio MJ, et al. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol Cell 2004; 16:715-24.
6. Olive PL. The role of DNA single- and double-strand breaks in cell killing by ionising radiation. Radiat Res 1998;150:S42-S51.
7. Westphal CH, Hoyes KP, Canman CE, Huang X, Kastan MB, Hendry JH, et al. Loss of ATM radiosensitises multiple p53 null tissues. Cancer Res 1998;58:5637-9.
8. Sarkaria JN, Eshleman JS. ATM as a target for novel radiosensitizers. Semin Radiat Oncol 2001;11:316-27.
9. Durocher D, Jackson SP. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 2001;13:225-31.
10. Izzard RA, Jackson SP, Smith GCM. Competitive and non-competitive inhibition of the DNA dependent protein kinase. Cancer Res 1999;59: 2581-6.
11. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NMB, Orr AI, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64: 9152-9.
12. Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther 2009;8: 2894-902.
13. Vikhanskaya F, Colella G, Valenti M, Parodi S, D'Incalci M, Broggini M. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage. Clin Cancer Res 1999;5:937-41.
14. Moumen A, Masterson P, O'Connor M, Jackson SJ. hnRNP K: An HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell 2005;123:1065-78.
15. Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase (DNA-PK) inhibitor, NU7441. Cancer Res 2006;66: 5354-62.
16. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Committee of the National Cancer Research Institute. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;102:1555-77.
17. Potter GWH. Analysis of biological molecules: an introduction to principles, instrumentation and techniques. 1st ed. London, England: Chapman and Hall;1995.
18. Kim WJ, Vo QN, Shrivastar M, Lataxes TA, Brown KD. Aberrant meth-ylation of the ATM promoter correlates with increased radiosensitivity in human colorectal tumour cell line. Oncogene 2002;21:3864-71.
19. Takemura H, Rao VA, Sordet O, Furuta T, Miao ZH, Meng L, et al. Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks. J Biol Chem 2006;281:30814-23.
20. Lu Y, Condie A, Bennett JD, Fry MJ, Yuille MR, Shipley J. Disruption of the ATM gene in breast cancer. Cancer Genet Cytogenet 2001;126: 97-101.
21. Massague J. G1 cell cycle control and cancer. Nature 2004;432: 298-306.
22. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, et al. Preclinical evaluation of a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, AG14361, with significant anticancer chemo- and radio-sensitization activity. J Natl Cancer Inst 2004;96: 56-67.